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Abstract: Darunavir is a second-generation protease inhibitor designed to have antiviral 
efﬁ  cacy against HIV-1 isolates harboring multiple resistance mutations to protease inhibitors. 
Pivotal trials conducted in treatment-experienced HIV-infected individuals have demonstrated 
signiﬁ  cantly greater virological suppression when darunavir was added to an optimized 
background treatment compared with a control protease inhibitor. This virological suppres-
sion was associated with an increase in CD4 counts and was sustained over time. Darunavir 
resistance-associated mutations have been deﬁ  ned as V11I, V32I, L33F, I47V, I50V, I54L/M, 
G73S, L76V, I84V, and L89V. In clinical trials, baseline darunavir susceptibility was a strong 
predictor of virological response. Prior use of fosamprenavir was associated with darunavir 
resistance mutations. Darunavir has a high genetic barrier and has a distinct resistance proﬁ  le. 
Although some cross-resistance exists with other second-generation protease inhibitors such 
as tipranavir, different resistance mutation patterns have been observed upon failure to these 
regimens. It was found that mutations at 47V, 54M, 85V, and 73T were most prevalent in 
isolates resistant to both PIs. Mutations 48V, 50V, and 54L were associated with resistance 
to darunavir but not to tipranavir. 82S and 82T were associated with resistance to tipranavir 
but not to darunavir. Therefore, darunavir provides potent virological efﬁ  cacy as well as high 
genetic barrier that can be useful to preserve treatment options in HIV-infected, treatment-
experienced individuals.
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Introduction
Antiretroviral drug resistance has become a major challenge in designing treatment 
regimens for HIV-infected individuals, particularly those who have been exposed to 
serial monotherapy or dual-therapy before the advent of using combination antiret-
roviral (ARV) therapy that included non-nucleoside reverse transcriptase inhibitors 
(NNRTI) or protease inhibitors (PI) in the mid 1990s. In a cohort of 4306 patients 
having started ARV therapy with 2 nucleoside analogs and a third agent, the risk 
of developing resistance over 6 years was 27%. The prevalence of resistance to 2 
and 3 classes of ARVs in this chronically infected population was estimated to be 
20% and 5%, respectively (Kuritzkes 2007). The development of new ARV agents 
active against drug-resistant isolates has brought new perspective on the treatment 
of HIV-infected, treatment-experienced individuals. Guidelines for the treatment of 
HIV-infected individuals, such as those developed by the International Aids Society-
USA (IAS-USA) or the US Department of Health and Human Services (US DHHS), 
recommend that achieving plasma viral loads 50 copies/mL should be the goal 
for all treated individuals, including highly treatment-experienced ones (Hammer 
et al 2006; DHHS 2008). Pivotal studies that led to these recommendations include 
the TORO, RESIST, and POWER trials that studied enfuvirtide, ritonavir-boosted 
tipranavir, and darunavir, respectively. Here the role of darunavir in our therapeutic 
armamentarium is reviewed.Therapeutics and Clinical Risk Management 2008:4(4) 760
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Darunavir pre-clinical development 
and in vitro resistance studies
Darunavir exhibits potent HIV antiviral activity in vitro with 
a 50% effective concentration (EC50) of 1 to 5 nM and a 
90% effective concentration of 2.7 to 13 nM (De Meyer 
et al 2005). Darunavir is well absorbed, and its bioavail-
ability increases by 30% when given with food. Darunavir is 
approximately 95% bound to plasma proteins. It is metabo-
lized by and inhibits cytochrome P-450 (CYP) isoenzyme 
3A4; therefore, darunavir is prone to CYP3A4-mediated 
drug – drug interactions (Surleraux et al 2005; Busse and 
Penzak 2007).
Mechanisms
Darunavir is a second-generation PI speciﬁ  cally designed to 
be active against PI-resistant HIV-1 isolates. HIV protease 
(PR) cleaves large gag-pol polyproteins into smaller proteins 
such as p24, p17, and p7, p6, p2, and p1, that are necessary 
for HIV assembly and RNA packaging resulting in infectious 
virions (Flexner 1998). PIs inhibit this enzyme by binding to 
its active site. Structure-based design of HIV-1 PIs that can 
speciﬁ  cally interact with the enzyme backbone atoms has 
led to stereochemically deﬁ  ned bis(tetrahydrofuranyl)(THF) 
urethane as a non-peptidic P2 ligand (Ghosh et al 2007). 
This bis-THF group confers strong hydrogen binding to the 
active site of the enzyme. Its binding afﬁ  nity for the wild-
type enzyme is 2 orders of magnitude higher than that of 
ﬁ  rst-generation PI and maintains 1.5 orders of magnitude 
tighter binding to the multi-drug resistant enzyme (King et al 
2004). Structural analyses revealed that the close contact of 
darunavir with the main chains of the PR active-site amino 
acids (Asp-29 and Asp-30) is important for its potency 
and wide spectrum of activity against multi-PI-resistant 
HIV-1 variants (Koh et al 2003). Furthermore, because of 
its molecular ﬂ  exibility, it can adapt itself to the changing 
shape of a mutant PR (Ghosh et al 2006; Tie et al 2007). 
Using ultra-high resolution crystal structure analysis of the 
darunavir complex with PR containing the drug-resistant 
mutation V32I and M46L, it was shown that darunavir 
binds at two distinct sites, one in the active-site cavity and 
the second on the surface of one of the ﬂ  exible ﬂ  aps in 
the PR dimer (Kovalevsky et al 2006a). Further studies of 
PR variants containing mutations D30N, I50V, and L90M 
demonstrated various inhibition constants reﬂ  ecting dif-
ferent molecular interactions between the mutated PR and 
darunavir at each of these sites (Kovalevsky et al 2006b). It 
has also been shown that darunavir can block PR dimeriza-
tion (Koh et al 2007).
Pre-clinical studies have shown darunavir’s efﬁ  cacy 
against a panel of 19 recombinant clinical isolates carrying 
multiple PR mutations and demonstrating resistance to an 
average of 5 other PIs. It was also active against a major-
ity of 1500 PI-resistant recombinant viruses derived from 
clinical samples. In vitro selection of mutants resistant to 
darunavir starting from wild-type virus has proved to be 
extremely difﬁ  cult (Surleraux et al 2005). After 75 passages 
(260 days), mutations at R41T and K70E appeared, resulting 
in approximately 10-fold phenotypic resistance. However, 
when the selected mutations were introduced into a labora-
tory strain by site-directed mutagenesis, they had no effect 
on susceptibility to darunavir or other PIs (De Meyer et al 
2005). When this experiment was extended to 327 passages 
(1155 days), mutations developed at H69Q and V77I, with 
an additional 8 mutations in the gag gene (both inside and 




An initial Phase IIa randomized, open-label, controlled study 
was conducted at 15 sites in Europe with 50 HIV-1-infected 
patients who had taken multiple PIs. PIs in non-suppres-
sive regimens were replaced with darunavir/ritonavir (r) 
(300/100 or 600/100 mg twice daily, or 900/100 mg once 
daily), or left unchanged, for 14 days. Viral load responses 
in all darunavir/r groups (range, –0.56 to –0.81 log10 
copies/mL) were greater (p  0.001) than in the controls 
(–0.03 log10 copies/mL). HIV-1 RNA 400 copies/mL 
at any time during treatment was achieved by 40% in the 
darunavir/r groups and 8% in the control group (Arasteh 
et al 2005). This study showed substantial antiviral activity 
of darunavir/r and led to 2 Phase IIb studies, POWER 1 and 
POWER 2. Both studies were designed to address treatment 
strategies in highly treatment-experienced individuals but 
were conducted in different geographical areas. Baseline 
mean viral loads were 4.66 and 4.48 log10 c/mL and median 
CD4 counts were 106 and 179 cells/μL for POWER 1 and 
2, respectively (Katlama et al 2007).
In these studies, after 24-week dose-ﬁ  nding phases and 
efﬁ  cacy analyses, subjects continued on an optimized back-
ground regimen plus either darunavir/r 600/100 mg twice 
daily or a control PI. Combined data showed that 67 of 110 
(61%) darunavir/r treated subjects compared with 18 of 
120 (15%) of control subjects had viral load reductions of 
1 log10 copies/mL or greater from baseline (primary endpoint; 
difference in response rates 46%, 95% conﬁ  dence interval Therapeutics and Clinical Risk Management 2008:4(4) 761
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[CI] 35%–57%, p  0.0001). Based on a logistic regression 
model including stratiﬁ  cation factors (baseline number of 
primary PI mutations, use of enfuvirtide, baseline viral load) 
as covariates, the difference in response was 50% (odds 
ratio 11.72, 95% CI 5.75–23.89). A mean CD4 increase 
of 102 cells/mm3 was observed in the darunavir/r arms vs 
19 cells/mm3 in the comparator arms. In the darunavir/r 
groups, rates of adverse events were mostly lower than or 
similar to those in the control groups, when corrected for 
treatment exposure (Clotet et al 2007). These impressive 
results in the Phase IIb studies at 48 weeks led to US FDA 
approval of darunavir in 2006.
Additional safety data were obtained in the POWER 3 
trial (Molina et al 2007). Treatment-experienced HIV-1-
infected subjects received darunavir/r at a dose of 600/100 
mg twice daily plus an optimized background regimen. 
Subjects treated numbered 327; the baseline mean HIV-1 
RNA was 4.6 log10 copies/mL, and the median CD4 count 
was 115 cells/mm3 (median primary PI mutations = 3, PI 
resistance-associated mutations = 9). By the cutoff date 246 
subjects reached week 24 and were included in the efﬁ  cacy 
analysis: 65% and 40% achieved HIV-1 RNA reductions 
of 1 log10 and 50 copies/mL, respectively, at week 24. The 
mean CD4 count increase was 80 cells/mm3. The most com-
mon adverse events were diarrhea (14%), nasopharyngitis 
(11%), and nausea (10%). These results corroborated those 
of POWER 1 and POWER 2. In all treatment-experienced 
clinical trials, darunavir has been relatively well tolerated. 
Few cases of hepatotoxicity have been observed in the post-
marketing surveillance program (monography).
In POWER 1, 2, and 3, 11 mutations in the PR enzyme 
were associated with decreased responses to darunavir (V11I, 
V32I, L33F, I47V, I50V, I54L/M, G73S, L76V, I84V, and 
L89V). Baseline darunavir susceptibility was a strong predic-
tor of virological response (Mascolini et al 2007). A 10-fold 
or less change in baseline susceptibility to darunavir resulted 
in a decrease in viral load of 2.08 log10 copies/mL at 24 weeks, 
whereas a 10- to 40-fold change resulted in a decrease of 
1.08 log10 copies/mL and a 40-fold change, 0.76 log10 copies/
mL. The proportion of subjects achieving 50 copies/mL of 
HIV RNA was 50%, 25%, and 13% respectively. Mutations 
had varying impact on phenotypic susceptibility. Mutations 
V11I, I54L, G73S, and L89V were associated with a 2-fold 
decrease in susceptibility; V32I, L33F, and I47V, 2- to 3-
fold; I54M, L76V, and I84V, 3- to 4-fold; I50V, greater than 
4-fold. The number of subjects achieving undetectable viral 
load was correlated with the number of mutations at baseline: 
64% with no mutations, 50%, 42%, 22%, and 10% with 1, 
2, 3, and 4 mutations respectively (De Meyer et al 2006, 
2008; Vangeneugden 2006; Kuritzkes 2007). Recent trials 
evaluated a new NNRTI, etravirine, in addition to a treatment 
regimen containing darunavir, in a treatment-experienced 
population. These DUET trials showed that when TMC-125 
(etravirine) was added to an optimized background contain-
ing darunavir/r, there was an added beneﬁ  t in the number 
of subjects reaching plasma viral loads 50 copies/mL 
(56% vs 39% in the placebo arm) as well as in the number 
of individuals with more than one log decrease in viral load 
(Lazzarin et al 2007; Madruga et al 2007b).
Moderately experienced patients
Darunavir/r was compared with lopinavir/r in a moder-
ately treatment-experienced population in the TITAN trial 
(Madruga et al 2007a). In this trial, patients received an opti-
mised background regimen plus non-blinded treatment with 
darunavir/r 600/100 mg twice daily or lopinavir/r 400/100 mg 
twice daily. Of 595 subjects randomized and treated, 187 
(31%) were PI-naïve; 476 of 582 (82%) were susceptible 
to 4 or more PIs. At study entry, median phenotypic sen-
sitivity score for the background regimen was 2.0 in both 
study arms, and trial participants had a median (range) of 0 
(0 to 6) primary PI mutations, 4 (0 to 17) primary or other PI 
mutations, 0 (0 to 5) darunavir-related mutations, 1 (0 to 11) 
lopinavir-related mutations, and 2 (0 to 8) nucleoside-related 
mutations. Median (range) fold change in susceptibility 
was 0.6 (0.1 to 43.8) for darunavir and 0.75 (0.3 to 74.5) 
for lopinavir. At week 48, more darunavir/r than lopinavir/r 
patients had plasma HIV RNA of less than 400 copies/mL 
(77% [220 of 286] vs 68% [199 of 293]; estimated differ-
ence 9%, 95% CI 2–16), meeting the primary end-point of 
non-inferiority (95% CI lower limit for the difference in 
treatment response –12% or greater). Furthermore, in the 
ITT analysis, the lower limit of the CI (2%) did not include 
0%, thereby meeting the a priori criterion for superiority. 
This was especially true in patients previously exposed to PI 
whose viruses harbored some resistance to PI. For subjects 
with viruses fully susceptible to protease inhibitors, both 
drugs performed similarly.
Darunavir resistance-associated mutations (RAMs) have 
been deﬁ  ned as V11I, V32I, L33F, I47V, I50V, I54L/M, 
G73S, L76V, I84V, and L89V. Lopinavir RAMS have been 
deﬁ  ned as L10F/I/R/V, K20M/R, L24I, V32I, L33F, M46I/
L, I47V/A, I50V, F53L, I54V/L/A/M/T/S, L63P, A71V/T, 
G73S, V82A/F/T/S, I84V, and L90M (Johnson et al 2007). 
The frequency of darunavir RAMs in this study was low. 
83% of patients’ baseline isolates had no darunavir RAMs. Therapeutics and Clinical Risk Management 2008:4(4) 762
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Only 4% of patients’ baseline isolates had 3 darunavir 
RAMs. A diminished response to darunavir/r was observed 
in patients with 3 darunavir RAMs at baseline; this sub-
group with 3 darunavir RAMs at baseline had a median 
number of 13 RAMs. The virological response to lopinavir/r 
was reduced (response 75% of the overall response) in 
patients with 2 darunavir RAMs or with 6 lopinavir RAMs 
at baseline. The presence of 6 lopinavir RAMs at baseline 
had no inﬂ  uence on response to darunavir/r; this subgroup 
had a median number of 12 RAMs (Johnson et al 2007). 
Fewer subjects with virological failures (VF) who were 
treated with darunavir/r developed primary protease inhibi-
tor mutations (21% [n = 6] vs 36% [n = 20]) and nucleoside 
analogue-associated mutations (14% [n = 4] vs 27% [n = 15]) 
than those treated with lopinavir/r. After excluding patients 
with lopinavir FC 10, the proportion of patients with VF 
developing primary PI mutations or NRTI RAMs was still 
higher in the lopinavir/r arm than the darunavir /r arm (33% 
vs 4%, and 23% vs 13%, respectively). Fewer patients with 
VF on darunavir/r than on LPV/r lost susceptibility com-
pared with baseline to the PI or an NRTI used in the treat-
ment regimen. The V32I mutation developed in 10% of 
patients with VF (3/28; 11%) on darunavir /r treatment. In 
this treatment-experienced, lopinavir-naïve TITAN patient 
population, higher response rates were observed at 48 weeks 
in the darunavir/r arm compared with the lopinavir/r arm, 
regardless of the number of darunavir RAMs or lopinavir 
RAMs at baseline. Virological response to darunavir/r was 
correlated with the number of darunavir RAMs at baseline, 
conﬁ  rming the results of the POWER trial analysis. The best 
virological responses (VL 50 or 400 copies/mL) were 
seen in patients with 0–1 darunavir RAMs (De Meyer et al 
2006, 2007). Safety data were similar between the groups; 
grade 3 or 4 adverse events occurred in 80 (27%) of daruna-
vir/r and 89 (30%) lopinavir/r patients.
Treatment-naïve individuals
The randomized, phase III ARTEMIS study was con-
ducted in 689 treatment-naïve subjects from 26 countries, 
and evaluated darunavir/r at a dose of 800/100 mg once 
daily vs lopinavir/r either 400/100 mg bid or 800/200 mg 
once daily, with tenofovir and emtricitabine. This patient 
population was predominantly male (70%), with a median 
CD4 count of 228 cells/mm3 and a median viral load of 
70,800 copies/mL. This study showed non-inferiority of 
darunavir/r compared with lopinavir/r, with 84% achieving 
viral load 50 copies/mL vs 78% in the lopinavir/r arm. In 
this trial, there was a 13% (95% CI 1; 24; p  0.05) better 
virological response in patients receiving darunavir/r vs 
lopinavir/r once daily (DeJesus et al 2007). Virological 
failure occurred in 10% of subjects in the darunavir/r arm 
vs 14% in the lopinavir/r arm. Among subjects with VF, 
only 1 patient, in the lopinavir/r arm, harbored a new PI 
resistance mutation, A71T, V77I. Three subjects (1 in the 
darunavir/arm and 2 in the lopinavir/r arm) developed the 
M184V/I. In this study, both regimens were well tolerated, 
with more diarrhea occurring in the lopinavir/r arm (10% 
vs 4%) and more rash in the darunavir/r arm (3% vs 1%) 
(Clumeck et al 2007). Darunavir/r is not presently licensed 
for the treatment of HIV-1 in treatment-naïve individuals.
Darunavir resistance proﬁ  le
In these pivotal clinical trials baseline darunavir susceptibility 
was predictive of virological response. Several studies have 
looked at the prevalence of darunavir-associated mutations 
in various populations. Table 1 summarizes the mutations 
associated with darunavir and tipranavir resistance. To esti-
mate to what extent darunavir might be effective in patients 
failing distinct PIs in a clinical setting, the genotypic resis-
tance scores for darunavir were examined in a large clinical 
HIV-1 drug resistance database. All clinical specimens from 
HIV-infected patients failing PI-based regimens referred for 
drug resistance testing between 1999 and 2007 to a reference 
centre in Madrid were analyzed. A total of 1021 genotypes 
from patients failing lopinavir (39.2%), nelﬁ  navir (28.1%), 
saquinavir (14.5%), indinavir (13.7%), atazanavir (6.6%), 
fosamprenavir (5.3%), and tipranavir (1.1%) were identi-
ﬁ  ed. The prevalence of major darunavir resistance mutations 
was: I50V 2.1%, I54M 1.3%, L76V 2.7%, and I84V 14.5%. 
For minor darunavir resistance mutations, the rates were: 
V11I 3.3%, V32I 3.9%, L33F 11%, I47V 2.1%, I54L 2.3%, 
G73S 12.8%, and L89V 2.4%. Overall, 6.7% (n = 68) of the 
genotypes had 3 or more darunavir resistance mutations, 
which corresponded to a mean total number of PI resistance 
mutations of 12.3 ± 1.9. In the multivariate analysis, prior 
fosamprenavir failure, prior saquinavir failure, the total 
number of PI resistance mutations, and the number of prior 
PIs used were all independently associated with having 
more darunavir resistance mutations (Poveda et al 2007). In 
another study of treatment-experienced individuals, patients 
harboring viruses with amprenavir-specific resistance 
proﬁ  les, such as I50V or V32I + I47V, failed on darunavir/
r-containing regimens. These key amprenavir mutations were 
also selected at the time of failure, suggesting their impact 
on darunavir efﬁ  cacy (Delaugerre et al 2007). Picchio and 
colleagues predicted phenotypic sensitivity to darunavir, Therapeutics and Clinical Risk Management 2008:4(4) 763
Role of darunavir in HIV treatment
using over 56,000 sample genotypes with different levels of 
PI resistance, from the Virco database from 2004–5 (Picchio 
et al 2006; Vermeiren et al 2007). Clinical and/or biologi-
cal cut-offs using upper and lower levels for each PI (3.4 
and 99.6 for darunavir) were used to determine the relative 
sensitivity to darunavir, deﬁ  ned as maximal, reduced, and 
minimal sensitivity. Darunavir showed a low proportion of 
samples (5%) with minimal and reduced responses. In a 
subgroup (n = 371) with minimal and reduced response to 
all PIs except darunavir and tipranavir, ~70% had minimal 
or reduced response to both PIs, ~20% had minimal or 
reduced response only to tipranavir with maximal response 
to darunavir, and 8% had minimal or reduced response to 
darunavir and maximal response to tipranavir.
Possible cross-resistance between tipranavir and daruna-
vir has been further analyzed. Baseline isolates for 1468 
patients from the RESIST trial and post-rebound isolates 
from 50 tipranavir-treated patients were sequenced and 
analyzed for Virtual Phenotype predicted IC50 fold change. 
For evaluation of cross-resistance, the clinical cut-offs of 1.2 
and 5.4 for tipranavir and 3.4 and 96.9 for darunavir were 
used. From the entire tipranavir database, baseline and on-
treatment genotypes were available and were analyzed for 
278 patients. It was found that mutations at 47V, 54M, 85V, 
and 73T were most prevalent in isolates resistant to both PIs. 
Mutations 48V, 50V, and 54L were associated with resistance 
to darunavir but not to tipranavir. 82S and 82T were associ-
ated with resistance to tipranavir but not to darunavir. 30N 
was associated with susceptibility to both drugs.
In patients from the RESIST trial, with baseline and 
on-treatment results, baseline isolates had median FC for 
tipranavir and darunavir of 1.6 and 3.55 respectively. After 
tipranavir treatment, medians were 8.4 and 2.5, respec-
tively. For the 80% (n = 40) of on-treatment isolates with 
tipranavir above the upper clinical cut-off, 55% were below 
the darunavir lower clinical cut-off. Loss of 48MAV, 50V, 
54ML, or 76V and emergence of 34D were associated with 
declining darunavir FC. Selection for 82T/L was not asso-
ciated with increased darunavir FC. In the larger tipranavir 
development program patient group (n = 278) the 82T/L 
mutation was the primary emergent mutation and there was 
a net loss of mutations at 48, 50, and 76. Mutations 20R, 
82T, and 82S are only at increased prevalence in isolates 
resistant to tipranavir and susceptible to darunavir. Muta-
tions at 46I, 10F, 13V, 32I, 33F, and 89V are prevalent in 
both cross resistant isolates and darunavir resistant/tipranavir 
susceptible isolates. Mutations at 50V and 54L are prevalent 
only in darunavir resistant/tipranavir susceptible isolates. For 
mutations 54M, 73T, 74P, or 85V nearly half of specimens 
were resistant to both tipranavir and darunavir. More than 
half of specimens with mutations 82F, 82S, or 82T were 
resistant to tipranavir and susceptible to darunavir. Almost 
80% of specimens with 50V mutation were resistant to 
darunavir and susceptible to tipranavir. More than half of 
specimens with mutations 20V, 32I, or 89V were resistant 
to both tipranavir and darunavir. Almost 85% of specimens 
with the 30N mutations were susceptible to both tipranavir 
and darunavir (Hall et al 2007).
Conclusion
Darunavir/r is presently approved for use in treatment-
experienced HIV-1 infected patients. In this population, it 
is recommended that 2 or more active agents be used when 
possible. These can be new agents from existing classes such 
as the new NNRTI etravirine (Lazzarin et al 2007; Madruga 
et al 2007b). Other agents from new classes such as integrase 
inhibitors or CCR5 inhibitors have shown substantial virologi-
cal and immunological efﬁ  cacy, and could also be used in 
combination with darunavir/r in this patient population (Carter 
and Keating 2007; Grinsztejn et al 2007; Stephenson 2007). 
Table 1 Resistance mutations associated with darunavir and tipranavir
Protease codons 10 20  30 40   50 60 70 80 90
VV L I I I G L I L
Darunavir II 3233 475054 73 76 84 89
II F V V M S V V V
L
LIK L E M K M I I Q HT V N IL
Tirpranavir 10 13 20 3335 36 43 46 47 54 58 69 74 82 8384 90
VVM F GIT LV AE K PLD VM
RM T
VTherapeutics and Clinical Risk Management 2008:4(4) 764
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The integrase inhibitor raltegravir, and the CCR5 inhibitor 
maraviroc, have both been approved for use in treatment-
experienced patients (Groeschen 2007; Traynor 2007).
Darunavir/r is an important addition to our treatment 
armamentarium in highly treatment-experienced individuals. 
It can provide a sustainable viral suppression in such patients, 
especially when combined with other active agents. Its high 
genetic barrier and its genetic resistance profile make it 
extremely useful in patients having failed a protease inhibitor 
containing regimen. The darunavir mutation score is distinct 
from the tipranavir mutation score, and this difference offers 
the clinician complementary options for subjects failing one or 
the other drug. In a modestly treatment-experienced population, 
darunavir/r can be a valuable option, particularly in subjects 
whose virus is resistant to lopinavir/r. Factors such as its strong 
genetic barrier for resistance development, relative pricing, and 
the available companion drugs to optimize the regimen back-
bone will need to be considered when contemplating its use in 
early treatment failure or in treatment-naïve populations.
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